Business
Ensysce Biosciences, Inc.: We depend heavily on the success of PF614 and PF614-MPAR product candidates, which are currently in clinical trials, and which may not be successful.
Revenue decreased 2.8% to $5.1M, while Net loss widened 27.4% to $10.2M.
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $5.1MWatch
- Profitability — Net loss $10.2MWatch
- Cash generation — Free cash flow −$7.9MNote
- Insiders — 0 buys; 0 sells in 365 daysNote
- Capital — Comparable payout data unavailableNote
Where the revenue comes from
Fiscal 2025, as Ensysce Biosciences, Inc. reports it. History and quarterly detail are in the app.
- MPAR$5.1M
Leadership changes
From Ensysce Biosciences, Inc.'s own filings, the day they're filed.
- Lynn Kirkpatrick · President · departureeff. 2026-08-05
- James Morrison · President · departureeff. 2026-08-05
- James Morrison · President · appointmenteff. 2026-08-04
Latest filings
- 8-K · Company announcement2026-09-29
- 8-K · Company announcement2026-08-25
- 8-K · Company announcement2026-08-24
- 8-K · Company announcement2026-08-13
- 10-Q · Quarterly report2026-08-13
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Ensysce Biosciences, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.